Granted Patent
B2
US 12,258,574 · App. 18/322,531 · Granted Mar 25, 2025
Methods and compositions for transducing lymphocytes and regulating the activity thereof
Inventors:
Gregory Ian Frost (West Palm Beach, FL); James Joseph Onuffer, Jr. (Alameda, CA); Ghiabe H. Guibinga (San Diego, CA); Farzad Haerizadeh (San Diego, CA); Anirban Kundu (Grand Cayman, KY)
Assignee:
Exuma Biotech Corp.
C12N15/86A61K39/461A61K39/4611A61K39/4631A61K39/464412A61K39/464499A61K39/464838C07K14/005C07K14/5418C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K14/70596C07K14/7155C07K16/2803C07K16/2809C07K16/2818C07K16/283C07K16/2863C07K16/30C07K16/32C12N5/0636C12N5/0646C12N15/1048C12N15/113C12N15/1138A61K2039/572A61K2239/31A61K2239/38C07K2317/622C07K2319/02C07K2319/03C07K2319/31C07K2319/32C07K2319/33C12N2310/12C12N2310/121C12N2310/141C12N2310/16C12N2310/531C12N2510/00C12N2740/10043C12N2740/10045C12N2740/10052C12N2740/16043C12N2740/16052C12N2760/18422C12N2800/30C12N2830/002C12N2830/008C12N2840/203
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
Claims (31)
1. A replication incompetent recombinant retroviral particle, comprising:
A. one or more envelope polypeptides;
B. a polynucleotide comprising one or more transcriptional units, wherein each of the one or more transcriptional units is operatively linked to a promoter active in T cells, and wherein the one or more transcriptional units encode:
i. a first engineered signaling polypeptide comprising a lymphoproliferative element wherein the lymphoproliferative element comprises a cytokine receptor polypeptide comprising a signaling domain that is capable of activating a Jak pathway, and promoting proliferation and/or survival of T cells; and
ii. a second engineered signaling polypeptide comprising an antigen specific targeting region (ASTR), a transmembrane domain, and an intracellular activating domain; and
C. an activation element on the surface of the replication incompetent recombinant retroviral particle, wherein the activation element is fused to a heterologous membrane attachment sequence, and wherein the activation element comprises a means for binding to CD3.
2. The replication incompetent recombinant retroviral particle of claim 1 , wherein the first engineered signaling polypeptide is encoded in a reverse orientation with respect to a cis-acting RNA packaging element in the genome of the recombinant retroviral particle.
3. The replication incompetent recombinant retroviral particle of claim 1 , wherein the promoter of at least one of the one or more transcriptional units is a T cell specific promoter.
4. The replication incompetent recombinant retroviral particle of claim 1 , wherein the promoter of at least one of the one or more transcriptional units is the EF1α promoter, the MSCV promoter, or the CD3ζ promoter.
5. The replication incompetent recombinant retroviral particle of claim 1 , wherein the polynucleotide further comprises an intron, and wherein the intron encodes a shRNA or one or more miRNAs.
6. The replication incompetent recombinant retroviral particle of claim 5 , wherein the intron is an EF1α intron.
7. The replication incompetent recombinant retroviral particle of claim 1 , wherein the first engineered signaling polypeptide coding sequence is operably linked to an intron in a first transcription unit of the one or more transcriptional units, and wherein the first transcriptional unit is in reverse orientation with respect to a cis-acting RNA packaging element in the genome of the recombinant retroviral particle.
8. The replication incompetent recombinant retroviral particle of claim 1 , wherein the signaling domain that is capable of activating a Jak pathway activates a STAT pathway, wherein the STAT pathway is a Stat1 pathway, a Stat3 pathway, a Stat4 pathway, or a Stat5 pathway.
9. The replication incompetent recombinant retroviral particle of claim 1 , wherein the signaling domain is an intracellular signaling domain of an IL-7 receptor, an intracellular signaling domain of an IL-12 receptor, an intracellular signaling domain of an IL-15 receptor, or an intracellular signaling domain of an IL-21 receptor.
10. The replication incompetent recombinant retroviral particle of claim 9 , wherein the signaling domain of the cytokine receptor polypeptide is the intracellular signaling domain of an IL-7 receptor, and wherein the IL-7 receptor is the IL-7Rα, or a functional fragment thereof.
11. The replication incompetent recombinant retroviral particle of claim 9 , wherein the signaling domain of the cytokine receptor polypeptide is the intracellular signaling domain of an IL-15 receptor, wherein the IL-15 receptor is the IL-2/IL-15R(3 or the common γ chain, or a functional fragment thereof.
12. The replication incompetent recombinant retroviral particle of claim 1 , wherein the lymphoproliferative element is constitutively active.
13. The replication incompetent recombinant retroviral particle of claim 12 , wherein the constitutively active lymphoproliferative element is an IL-7Rα mutant, or a functional fragment thereof.
14. The replication incompetent recombinant retroviral particle of claim 13 , wherein the IL-7Rα mutant comprises amino acids 229 to 292 of SEQ ID NO:229 with an insertion of PPCL at amino acid 243 of SEQ ID NO:229.
15. The replication incompetent recombinant retroviral particle of claim 1 , wherein the lymphoproliferative element is a fusion polypeptide comprising a recognition domain that is recognized by a monoclonal antibody approved biologic.
16. The replication incompetent recombinant retroviral particle of claim 1 , wherein the transcriptional unit encoding the first engineered signaling polypeptide further comprises a riboswitch.
17. The replication incompetent recombinant retroviral particle of claim 1 , further comprising a means for binding CD28.
18. The replication incompetent recombinant retroviral particle of claim 1 , wherein the intracellular activating domain comprises a CD3ζ intracellular activating domain.
19. The replication incompetent recombinant retroviral particle of claim 18 , wherein the ASTR comprises a single chain antibody.
20. The replication incompetent recombinant retroviral particle of claim 19 , wherein the single chain antibody is a scFv.
21. The replication incompetent recombinant retroviral particle of claim 1 , wherein one or more of the envelope polypeptides comprises a vesicular stomatitis virus (VSV-G) envelope protein, a feline endogenous virus (RD114) envelope protein, or a Paramyxoviridae envelope protein.
22. The replication incompetent recombinant retroviral particle of claim 1 , wherein the replication incompetent recombinant retroviral particle is a lentiviral particle.
23. The replication incompetent recombinant retroviral particle of claim 1 , wherein the recombinant retroviral particle further comprises a membrane-bound cytokine on the surface of the recombinant retroviral particle, wherein the membrane-bound cytokine comprises a fusion polypeptide of IL-7 and DAF, and wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:286.
24. The replication incompetent recombinant retroviral particle of claim 1 , wherein the replication incompetent recombinant retroviral particle further comprises CD80 on its surface.
25. The replication incompetent recombinant retroviral particle of claim 1 , wherein the replication incompetent recombinant retroviral particle further comprises CD86 on its surface.
26. The replication incompetent recombinant retroviral particle of claim 1 , wherein the means for binding to CD3 is an anti-CD3 scFv.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 23, 2024
From: FROST, GREGORY IAN; ONUFFER, JAMES JOSEPH, JR.; GUIBINGA, GHIABE H.; HAERIZADEH, FARZAD
To: F1 ONCOLOGY, INC.
Reel/Frame 067198/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2024
From: KUNDU, ANIRBAN
To: F1 ONCOLOGY, SEZC
Reel/Frame 067185/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2024
From: F1 ONCOLOGY, SEZC
To: F1 ONCOLOGY, INC.
Reel/Frame 067185/0544 →
CHANGE OF NAME
Recorded Apr 22, 2024
From: F1 ONCOLOGY, INC.
To: EXUMA BIOTECH CORP.
Reel/Frame 067188/0308 →
Continuity (9)
Continuation In Part
PCTUS2017023112
· Mar 19, 2017
Provisional Application
62467039
· Mar 3, 2017
Provisional Application
62360041
· Jul 8, 2016
Provisional Application
62390093
· Mar 19, 2016
References Cited (400)
US 5677425A
· Bodmer et al.
· 1997
[cited by applicant]
US 6531123B1
· Chang
· 2003
[cited by applicant]
US 8709755B2
· Short et al.
· 2014
[cited by applicant]
US 8802374B2
· Jensen
· 2014
[cited by applicant]
US 20040131637A1
· Chatfield
· 2004
[cited by applicant]
US 20080269258A1
· Breaker et al.
· 2008
[cited by applicant]
US 20120052082A1
· Compans et al.
· 2012
[cited by applicant]
US 20160251660A1
· Gu et al.
· 2016
[cited by applicant]
US 20170166877A1
· Bayle et al.
· 2017
[cited by applicant]
US 20170246278A1
· Valdes et al.
· 2017
[cited by applicant]
US 20170335281A1
· Loew et al.
· 2017
[cited by applicant]
US 20180021378A1
· Kang et al.
· 2018
[cited by applicant]
US 20190161542A1
· Gill et al.
· 2019
[cited by applicant]
US 20200397821A1
· Frost et al.
· 2020
[cited by applicant]
US 20210317408A1
· Frost et al.
· 2021
[cited by applicant]
US 20210403952A1
· Frost et al.
· 2021
[cited by applicant]
US 20220340927A1
· Frost et al.
· 2022
[cited by applicant]
US 20230044451A1
· Frost et al.
· 2023
[cited by applicant]
US 20230111159A1
· Frost et al.
· 2023
[cited by applicant]
US 20230257776A1
· Frost et al.
· 2023
[cited by applicant]
US 20230357436A1
· Frost et al.
· 2023
[cited by applicant]
US 20230392139A1
· Frost et al.
· 2023
[cited by applicant]
CN 104395463A
· 2015
[cited by applicant]
CN 107400664A
· 2017
[cited by applicant]
CN 10991342A
· 2019
[cited by applicant]
EP 2019144A1
· 2009
[cited by applicant]
JP 2015503907A
· 2015
[cited by applicant]
JP 2015513394A
· 2015
[cited by applicant]
WO 1993003769A1
· 1993
[cited by applicant]
WO 1993009239A1
· 1993
[cited by applicant]
WO 1993019191A1
· 1993
[cited by applicant]
WO 1994012649A2
· 1994
[cited by applicant]
WO 1994028938A1
· 1994
[cited by applicant]
WO 1995000655A1
· 1995
[cited by applicant]
WO 1995011984A2
· 1995
[cited by applicant]
WO 1995016784A1
· 1995
[cited by applicant]
WO 1995023846A1
· 1995
[cited by applicant]
WO 1996017951A2
· 1996
[cited by applicant]
WO 9621015A2
· 1996
[cited by applicant]
WO 1999004026A2
· 1999
[cited by applicant]
WO 1999034836A1
· 1999
[cited by applicant]
WO 2001029194A1
· 2001
[cited by applicant]
WO 2001074861A2
· 2001
[cited by applicant]
WO 2001089580A1
· 2001
[cited by applicant]
WO 2002018609A2
· 2002
[cited by applicant]
WO 0226240A2
· 2002
[cited by applicant]
WO 2004073641A2
· 2004
[cited by applicant]
WO 2005014027A1
· 2005
[cited by applicant]
WO 2005118802A2
· 2005
[cited by applicant]
WO 2006007539A1
· 2006
[cited by applicant]
WO 2005110491A3
· 2006
[cited by applicant]
WO 2006055351A2
· 2006
[cited by applicant]
WO 2006089001A2
· 2006
[cited by applicant]
WO 2007008918A2
· 2007
[cited by applicant]
WO 2008156987A2
· 2008
[cited by applicant]
WO 2008037458A2
· 2009
[cited by applicant]
WO 2009120947A1
· 2009
[cited by applicant]
WO 2010062757A1
· 2010
[cited by applicant]
WO 2011053991A2
· 2011
[cited by applicant]
WO 2011059836A2
· 2011
[cited by applicant]
WO 2011100460A2
· 2011
[cited by applicant]
WO 2012079000A1
· 2012
[cited by applicant]
WO 2012138858A1
· 2012
[cited by applicant]
WO 2012153142A2
· 2012
[cited by applicant]
WO 2013045639A1
· 2013
[cited by applicant]
WO 2013092720A1
· 2013
[cited by applicant]
WO 2013123061A1
· 2013
[cited by applicant]
WO 2013127964A1
· 2013
[cited by applicant]
WO 2013166051A1
· 2013
[cited by applicant]
WO 2013188864A2
· 2013
[cited by applicant]
WO 2014011984A1
· 2014
[cited by applicant]
WO 2014028509A2
· 2014
[cited by applicant]
WO 2014028509A3
· 2014
[cited by applicant]
WO 2014130657A1
· 2014
[cited by applicant]
WO 2014138306A1
· 2014
[cited by applicant]
WO 2014151960A2
· 2014
[cited by applicant]
WO 2014153270A1
· 2014
[cited by applicant]
WO 2014153636A1
· 2014
[cited by applicant]
WO 2014186469A2
· 2014
[cited by applicant]
WO 2015056980A1
· 2015
[cited by applicant]
WO 2015066042A1
· 2015
[cited by applicant]
WO 2015075195A1
· 2015
[cited by applicant]
WO 2016009326A1
· 2016
[cited by applicant]
WO 2016016344A1
· 2016
[cited by applicant]
WO 2016030691A1
· 2016
[cited by applicant]
WO 2016033331A1
· 2016
[cited by applicant]
WO 2016061574A1
· 2016
[cited by applicant]
WO 2016073602A2
· 2016
[cited by applicant]
WO 2016118857A1
· 2016
[cited by applicant]
WO 2016139463A1
· 2016
[cited by applicant]
WO 2017011804A1
· 2017
[cited by applicant]
WO 2017011804A8
· 2017
[cited by applicant]
WO 2017034615A1
· 2017
[cited by applicant]
WO 2017068419A2
· 2017
[cited by applicant]
WO 2017103596A1
· 2017
[cited by applicant]
WO 2017165245A2
· 2017
[cited by applicant]
WO 2017182585A1
· 2017
[cited by applicant]
WO 2017165245A3
· 2017
[cited by applicant]
WO 2017201635A1
· 2017
[cited by applicant]
WO 2018009923A1
· 2018
[cited by applicant]
WO 2018033726A1
· 2018
[cited by applicant]
WO 2018038945A1
· 2018
[cited by applicant]
WO 2018075978A1
· 2018
[cited by applicant]
WO 2018136570A1
· 2018
[cited by applicant]
WO 2018136570A9
· 2018
[cited by applicant]
WO 2018161064A1
· 2018
[cited by applicant]
WO 2018161064A9
· 2018
[cited by applicant]
WO 2018175476A1
· 2018
[cited by applicant]
WO 2018208728A1
· 2018
[cited by applicant]
WO 2018226897A1
· 2018
[cited by applicant]
WO 2019034703A2
· 2019
[cited by applicant]
WO 2019055946A1
· 2019
[cited by applicant]
WO 2019152692A1
· 2019
[cited by applicant]
WO 2019157130A1
· 2019
[cited by applicant]
WO 2019161281A1
· 2019
[cited by applicant]
WO 2019169290A1
· 2019
[cited by applicant]
WO 2019178677A1
· 2019
[cited by applicant]
WO 2019200056A2
· 2019
[cited by applicant]
WO 2019222403A2
· 2019
[cited by applicant]
WO 2020014209A1
· 2020
[cited by applicant]
WO 2020047387A1
· 2020
[cited by applicant]
WO 2020047527A2
· 2020
[cited by applicant]
WO 2020069463A1
· 2020
[cited by applicant]
WO 2020047527A3
· 2020
[cited by applicant]
WO 2020106992A1
· 2020
[cited by applicant]
WO 2020119048A1
· 2020
[cited by applicant]
WO 2020102503A2
· 2020
[cited by applicant]
WO 2020210678A1
· 2020
[cited by applicant]
WO 2020257423A1
· 2020
[cited by applicant]
WO 2021042072A1
· 2021
[cited by applicant]
WO 2021046143A1
· 2021
[cited by applicant]
WO 2021076788A2
· 2021
[cited by applicant]
WO 2021178701A1
· 2021
[cited by applicant]
WO 2021178701A9
· 2021
[cited by applicant]
WO 2022047417A1
· 2022
[cited by applicant]
WO 2022187289A1
· 2022
[cited by applicant]
WO 2023168305A1
· 2023
[cited by applicant]
May et al: “Comparative study on the phosphotyrosine motifs of different cytokine receptors involved in STAT5 activation”, FEBS Lett. 394(2):221-6, Sep. 30, 1996.
[cited by applicant]
McElroy CA et al: “Structural reorganization of the interleukin-7 signaling complex”, Proceedings of the National Academy of Sciences, 109(7):2503-2508, Jan. 30, 2012.
[cited by applicant]
McKelvie ND et al: “Expression of heterologous antigens in
[cited by applicant]
Melton DA et al: “Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter”, Nucleic Acids Research, 12(18):7035-7056, Sep. 25, 1984.
[cited by applicant]
Mendelson et al., “Expression and rescue of a nonselected marker from an integrated AAV vector”, Virology, vol. 166, No. 1, May 22, 1988, pp. 154-165, doi: 10.1016/0042-6822(88)90157-2.
[cited by applicant]
Meng et al., “c-Jun, at the crossroad of the signaling network”, Protein Cell. Nov. 2011;2(11):889-98. doi: 10.1007/s13238-011-1113-3. Epub Dec. 17, 2011. PMID: 22180088; PMCID: PMC4875184.
[cited by applicant]
Micheau, Olivier, and Jürg Tschopp. “Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes.” Cell 114.2 (2003): 181-190.
[cited by applicant]
Miller, “Human gene therapy comes of age”, Nature, vol. 357, No. 6378, 1992, Jun. 11, 1992, pp. 455-460, doi: 10.1038/357455a0.
[cited by applicant]
Miyoshi et al., “Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector”, Proceedings of the National Academy of Sciences, vol. 94, No. 19, Sep. 1997, pp. 10319-10323, doi:10.1073/pnas.9…
[cited by applicant]
Moore, K L. “Structure and function of P-selectin glycoprotein ligand-1.” Leukemia & lymphoma vol. 29,1-2 (1998): 1-15. doi:10.3109/10428199809058377.
[cited by applicant]
Morella KK et al: “Signal transduction by the receptors for thrombopoietin (c-mpL) and interleukin-3 in hematopoietic and nonhematopoietic cells”, Blood 86(2):557-571 Jul. 15, 1995.
[cited by applicant]
Morgan RA et al: “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2”, Molecular Therapy, 18(4):843-851, Feb. 23, 2010.
[cited by applicant]
Morizono et al.: “Antibody-directed targeting of retroviral vectors via cell surface antigens”, J Virol. Sep. 2001;75 (17):8016-20.
[cited by applicant]
Mühlebach et al., “Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes”, Journal of Molecular Medicine, 81(12):801-810, Oct. 24, 2003.
[cited by applicant]
Murakami et al: “Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family”, Proc Natl Acad Sci U S A 88(24):11349-53, Dec. 15, 1991.
[cited by applicant]
Nam S et al: “Driving the next wave of innovation in CAR T-cell therapies”, McKinsey & Company Pharmaceuticals & Medical Products, Dec. 13, 2019.
[cited by applicant]
Ngo MC et al: “Ex vivo gene transfer for improved adoptive immunotherapy of cancer”, Human Molecular Genetics, 20(R1):R93-R99, Mar. 17, 2011.
[cited by applicant]
Nguyen V-T et al: “Multiple GO-SELEX for efficient screening of flexible aptamers”, Chemical Communications, 50 (72):10513-10516, Jul. 23, 2014.
[cited by applicant]
Nishimura CD et al: “c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals”, Blood 130(25):2739-2749 Dec. 21, 2017.
[cited by applicant]
O'Connor CM et al: “Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy”, Scientific Reports, vol. 2, Feb. 1, 2012.
[cited by applicant]
Ogawa A: “Rational design of artificial riboswitches based on ligand-dependent modulation of internal ribosome entry in wheat germ extract and their applications as label-free biosensors”, RNA, 17(3):478-488, Jan. 11, 2…
[cited by applicant]
Ohno et al: “Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts”, Journal for Immunotherapy of Cancer, 1:21, …
[cited by applicant]
Okamoto S et al: “A promising vector for TCR gene therapy: differential effect of siRNA, 2A peptide, and disulfide bond on the introduced TCR expression”, Molecular Therapy—Nucleic Acids, 1(12):e63, Dec. 18, 2012.
[cited by applicant]
O'Neill LS et al: “Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles”, Journal of Gene Medicine, 12(5):463-476, May 2010.
[cited by applicant]
Otto KG et al: “Membrane localization is not required for Mpl function in normal hematopoietic cells”, Blood 98 (7):2077-2083 Oct. 1, 2001.
[cited by applicant]
Papapetrou EP et al: “Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras”, Journal of Clinical Investigation, 119…
[cited by applicant]
Papathanasiou et. al., “Autologous CAR T-cell therapies supply chain: challenges and opportunities?”, Cancer Gene Therapy, vol. 27, Jan. 14, 2020, pp. 799-809, doi: 10.1038/s41417-019-0157-z.
[cited by applicant]
Park JW et al: “Immobilization-free screening of aptamers assisted by graphene oxide”, Chem. Commun., 48 (15):2071-2073, Dec. 5, 2011.
[cited by applicant]
Patel N et al: “Functional Replacement of Cytokine Receptor Extracellular Domains by Leucine Zippers”, Journal of Biological Chemistry 271(48):30386-30391 Nov. 29, 1996.
[cited by applicant]
Pecquet C et al: “Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor”, Blood 115(5):1037-1048 Feb. 4, 2010.
[cited by applicant]
Pikovskaya O et al: “Structural principles of nucleoside selectivity in a 2′-deoxyguanosine riboswitch”, Nature chemical biology, 7(10):748, Aug. 14, 2011.
[cited by applicant]
Poling BC et al: “A lentiviral vector bearing a reverse intron demonstrates superior expression of both proteins and microRNAs”, RNA Biology, 14(11):1570-1579, Jul. 21, 2017.
[cited by applicant]
Pulkkinen WS et al: “A
[cited by applicant]
Reid CA et al: “Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD”, Scientific reports, 8(1):11763, Aug. 6, 2018.
[cited by applicant]
Richard et al: “Differences in F36VMpl-Based in Vivo Selection among Large Animal Models”, Molecular Therapy 10 (4):730-740, Oct. 2004.
[cited by applicant]
Richard RE et al: “Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization”, Blood 95(2):430-436 Jan. 15, 2000.
[cited by applicant]
Rolling et al., “Evaluation of Adeno-Associated Virus-Mediated Gene Transfer into the Rat Retina by Clinical Fluorescence Photography”, Human Gene Therapy, vol. 10, No. 4, Mar. 1, 1999, pp. 641-648, doi: 10.1089/1043034…
[cited by applicant]
Rommel et al: “Signaling properties of murine MPL and MPL mutants after stimulation with thrombopoietin and romiplostim”, Experimental Hematology 85, 33-46.e6, May 2020.
[cited by applicant]
Royer et al: “Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability”, Journal of Biological Chemistry 280(29):27251-27261, Jul. 2005.
[cited by applicant]
Saka K et al: “Activation of target signal transducers utilizing chimeric receptors with signaling-molecule binding motifs”, Biotechnology and Bioengineering 109(6):1528-1537 Jun. 2012.
[cited by applicant]
Saka K et al: “Dissection of Signaling Events Downstream of the c-Mpl Receptor in Murine Hematopoietic Stem Cells Via Motif-Engineered Chimeric Receptors”, Stem Cell Reviews and Reports 14(1):101-109 Feb. 2018.
[cited by applicant]
Sakamoto et al., “A vitrectomy improves the transfection efficiency of adenoviral vector-mediated gene transfer to Müller cells”, Gene Therapy, vol. 5, No. 8, Mar. 11, 1998, pp. 1088-1097, doi: 10.1038/sj.gt.3300701.
[cited by applicant]
Salmon et. al., “Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promoter is tissue-specific and is activated by Ets proteins”, Proceedings of the National Academy of Sciences, vol.…
[cited by applicant]
Samulski et al., “Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression”, Journal of Virology, vol. 63, No. 9, Jun. 1, 1989, pp. 3822-3828, doi: 10.1128/JV…
[cited by applicant]
Saur et al: “Ubiquitination and degradation of the thrombopoietin receptor c-Mpl”, Blood 115(6):1254-63, Feb. 11, 2010.
[cited by applicant]
Schütze T et al: “Probing the SELEX Process with Next-Generation Sequencing”, PLoS ONE, 6(12):e29604, Dec. 29, 2011.
[cited by applicant]
Shaner NC et al: “A guide to choosing fluorescent proteins”, Nature Methods, 2(12):905-909, Dec. 2005.
[cited by applicant]
Sharma S et al: “Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector”, Proceedings National Academy of Sciences, vol. 93, No. 21, Jan. 1, 1996…
[cited by applicant]
Shetron-Rama LM et al.: “Intracellular Induction of Listeria monocytogenes actA Expression”, Infection and Immunity, 70(3):1087-1096, Mar. 2002.
[cited by applicant]
Shilova, O N, and S M Deyev. “DARPins: Promising Scaffolds for Theranostics.” Acta naturae vol. 11,4 (2019): 42-53. doi:10.32607/20758251-2019-11-4-42-53.
[cited by applicant]
Shochat C et al: “Gain-of-function mutations in interleukin-7 receptor-? (IL7R) in childhood acute lymphoblastic leukemias”, Journal of Experimental Medicine, 208(5):901-908, May 2, 2011.
[cited by applicant]
Shochat C et al: “Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia”, Blood, 124(1):106-110, May 1, 2014.
[cited by applicant]
Shum T et al: “Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells”, Cancer Discovery, 7(11):1238-1247, Aug. 22, 2017.
[cited by applicant]
Speeckaert, Marijn M et al. “Biological and clinical aspects of soluble transferrin receptor.” Critical reviews in clinical laboratory sciences vol. 47,5-6 (2010): 213-28. doi:10.3109/10408363.2010.550461.
[cited by applicant]
Staerk J et al: “Orientation-specific signalling by thrombopoietin receptor dimers: Orientation-specific TpoR signalling”, EMBO Journal, 30(21):4398-4413, Sep. 2, 2011.
[cited by applicant]
Stahl et al: “Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors”, Science 267(5202):1349-53, Mar. 3, 1995.
[cited by applicant]
Strebel K et al: “Human cellular restriction factors that target HIV-1 replication”, BMC Medicine, 7:48, Dec. 2009.
[cited by applicant]
Sun J et al: “The quest for spatio-temporal control of CAR T cells”, Cell Research, 25(12):1281-1282, Nov. 17, 2015.
[cited by applicant]
Sun, Shuyang et al. “Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.” International journal of nanomedicine vol. 16 2337-2356. Mar. 22, 2021, doi:10.2147/IJN.S297631.
[cited by applicant]
Takahashi et al., “Rescue from Photoreceptor Degeneration in the rd Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer”, Journal of Virology, vol. 73, No. 9, Sep. 1999, pp. 7812-7816, doi: 10.1128/JVI.7…
[cited by applicant]
Testi, R et al. “The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells.” Immunology today vol. 15,10 (1994): 479-83. doi:10.1016/0167-5699(94)90193-7.
[cited by applicant]
Till et al: “CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1 BB domains: pilot clinical trial results.”, Blood, Apr. 25, 2012, vol. 119, No. 17, pp. 3940-3950.
[cited by applicant]
Tone Y et al: “Cell fate conversion by conditionally switching the signal-transducing domain of signalobodies: Cell Fate Conversion by Signalobodies”, Biotechnology and Bioengineering, 110(12):3219-3226, Dec. 2013.
[cited by applicant]
Tong et al: “The Membrane-proximal Region of the Thrombopoietin Receptor Confers Its High Surface Expression by JAK2-dependent and -independent Mechanisms”, Journal of Biological Chemistry 281(50): 38930-38940, Dec. 200…
[cited by applicant]
Townshend B et al: “High-throughput cellular RNA device engineering”, Nature methods, 12(10):989-994, Aug. 10, 2015.
[cited by applicant]
Tsutsumi, Hiroshi, et al. “Fluorogenically active leucine zipper peptides as tag-probe pairs for protein imaging in living cells.” Angewandte Chemie International Edition 48.48 (2009): 9164-9166.
[cited by applicant]
Unutmaz D et al: “Cytokine Signals Are Sufficient for HIV-1 Infection of Resting Human T Lymphocytes”, Journal of Experimental Medicine, 189(11):1735-1746, Jun. 7, 1999.
[cited by applicant]
Valdivia RH et al: “Bacterial genetics by flow cytometry: rapid isolation of
[cited by applicant]
Van Der Geer et al: “Identification of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites”, Proc Natl Acad Sci U S A. 93(3):963-8, Feb. 6, 1996.
[cited by applicant]
Varghese et al: “The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin”, Front Endocrinol (Lausanne) ; 8:59, Mar. 31, 2017.
[cited by applicant]
Verhoeyen E et al: “IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes”, Blood, vol. 101, No. 6, Mar. 15, 2003, pp. 2167-2174.
[cited by applicant]
Verhoeyen et. al., “Lentiviral vector gene transfer into human T cells”, Antibody-Drug Conjugates In: Methods In Molecular Biology, vol. 506, Feb. 2009, pp. 97-114, Humana Press, DOI: 10.1007/978-1-59745-409-4_8, XP0091…
[cited by applicant]
Vigant F et al: “Same day transduction and in vivo expansion of chimeric antigen receptors and synthetic driver constructs for adoptive cellular therapy”, Cancer research: Proceedings: AACR Annual Meeting 2019, Mar. 29-…
[cited by applicant]
Vormittag et. al., “A guide to manufacturing CAR T cell therapies”, Current Opinion In Biotechnology, vol. 53, Oct. 2018, pp. 164-181, doi: 10.1016/j.copbio.2018.01.025.
[cited by applicant]
Vu MM et al: “Convergent evolution of adenosine aptamers spanning bacterial, human, and random sequences revealed by structure-based bioinformatics and genomic SELEX”, Chemistry & biology, 19(10):1247-1254, Oct. 25, 201…
[cited by applicant]
Wajant, H., K. Pfizenmaier, and P. Scheurich. “Tumor necrosis factor signaling.” Cell Death & Differentiation 10.1 (2003): 45-65.
[cited by applicant]
Walsh STR: “Structural insights into the common ?-chain family of cytokines and receptors from the interleukin-7 pathway”, Immunological Reviews, 250(1):303-316, Nov. 2012.
[cited by applicant]
Wang et al., “Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale”, Journal of Immunotherapy, vol. 35, No. 9, Nov.-Dec. 2012, pp. 68…
[cited by applicant]
Wang J et al: “Particle Display: A Quantitative Screening Method for Generating High-Affinity Aptamers*”, Angewandte Chemie International Edition, 53(19):4796-4801, Mar. 18, 2014.
[cited by applicant]
Wang Y et al: “An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment”, Frontiers in Immunology, 10:1691, Jul. 19, 2019.
[cited by applicant]
Welz R et al: “Ligand binding and gene control characteristics of tandem riboswitches in Bacillus anthracis”, RNA, 13 (4):573-582, Feb. 16, 2007.
[cited by applicant]
Wilkie S et al: “Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4”, Journal of Biological Chemistry, vol. 285, No. 33, Jun. 18, 2010, pp. 25538-25544.
[cited by applicant]
Wu C-Y et al: “Remote control of therapeutic T cells through a small molecule-gated chimeric receptor”, Science, 350 (6258):aab4077, Sep. 24, 2015.
[cited by applicant]
Xu et al., “Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15”, Blood, vol. 23, No. 24, Jun. 12, 2014, pp. 3750-3759, doi: 10.1182/blood-2014-01…
[cited by applicant]
Xu, Zhuwei, and Boquan Jin. “A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions.” Cellular & molecular immunology vol. 7,1 (2010): 11-9. doi:10.1038/cmi.2009.108.
[cited by applicant]
Yan et al., “Engineering Upper Hinge Improves Stability and Effector Function of a Human IgG1”, Journal Of Biological Chemistry, vol. 287, No. 8, Feb. 17, 2012, pp. 5891-5897.
[cited by applicant]
Yang et al., “Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule”, Pharmaceutical Research, vol. 26, No. 6, Mar. 4, 2009, pp. 1432-1445.
[cited by applicant]
Yang L et al: “Targeting lentiviral vectors to specific cell types in vivo”, Proceedings of the National Academy of Sciences, 103(31):11479-11484, Jul. 24, 2006.
[cited by applicant]
Yang, Yang, et al. “Structural Insights Into Central Hypertension Regulation By Human Aminopeptidase A.” The Journal of Biological Chemistry, vol. 288, No. 35, 2013, pp. 25638-25645.
[cited by applicant]
Yokoyama K et al: “In vivo leukemogenic potential of an interleukin 7 receptor ? chain mutant in hematopoietic stem and progenitor cells”, Blood, 122(26):4259-4263, Oct. 30, 2013.
[cited by applicant]
Yoon H et al: “An efficient strategy for cell-based antibody library selection using an integrated vector system”, BMC Biotechnology, 12:62, Sep. 18, 2012.
[cited by applicant]
Zapata et al., “Engineering linear F(ab′)2 fragments for efficient production in
[cited by applicant]
Zenatti PP et al: “Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia”, Nature Genetics, 43(10):932-939, Sep. 4, 2011.
[cited by applicant]
Zeng S et al: “Exploration on the mechanism of DNA adsorption on graphene and graphene oxide via molecular simulations”, Journal of Physics D: Applied Physics, 48(27):275402, Oct. 10, 2015.
[cited by applicant]
Zhang X et al: “Tumor pH and Its Measurement”, Journal of Nuclear Medicine, 51(8):1167-1170, Jul. 21, 2010.
[cited by applicant]
Zhao et al., “Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor” Cancer Research, vol. 70, Issue 22, p. 9053-9061, doi: 10.115…
[cited by applicant]
Zhao S et al: “In Vivo Selection of Genetically Modified Erythroid Cells Using a Jak2-Based Cell Growth Switch”, Molecular Therapy 10(3):456-468 Sep. 2004.
[cited by applicant]
Zhao S: “JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells”, The EMBO Journal 21(9):2159-2167 May 1, 2002.
[cited by applicant]
Zhen et al., “HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells”, Molecular Therapy, vol. 23, Issue 8, Aug. 2015, pp. 1358-1367, doi: 10.1038/mt.2015.102.
[cited by applicant]
Zichel R et al: “Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins”, PloS One, 7(2): e31948, Feb. 27, 2012.
[cited by applicant]
Zuker M: “Mfold web server for nucleic acid folding and hybridization prediction”, Nucleic Acids Research, 31 (13):3406-3415, Jul. 1, 2003.
[cited by applicant]
Jensen MC: “Enhancing the IQ of CAR-modified T Cells”, International Society & Gene Therapy abstract, Jun. 1, 2012.
[cited by applicant]
Ji et al: “Enhancing adoptive T cell immunotherapy with microRNA therapeutics”, Seminars in immunology, 28 (1):45-53, Dec. 20, 2015.
[cited by applicant]
Johnson, G., & Wu, T. T. (2000). Kabat database and its applications: 30 years after the first variability plot. Nucleic acids research, 28(1), 214-218.
[cited by applicant]
Johnson, G., & Wu, T. T. (2001). Kabat Database and its applications: future directions. Nucleic Acids Research, 29 (1), 205-206.
[cited by applicant]
Jomary et al., “Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration”, Gene Therapy, vol. 4, No. 7, 1997, pp. 683-690, doi:10.1038/sj.gt.3300440.
[cited by applicant]
Jones et al., “Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes”, Human Gene Therapy, vol. 20, No. 6, Jun. 2009,…
[cited by applicant]
Kagoya Y et al: “A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects”, Nature Medicine, 24(3):352, Feb. 5, 2018.
[cited by applicant]
Kaiser AD et al: “Towards a commercial process for the manufacture of genetically modified T cells for therapy”, Cancer Gene Therapy, 22(2):72-78, Jan. 23, 2015.
[cited by applicant]
Kawahara M et al“Growth promotion of genetically modified hematopoietic progenitors using an antibody/c-Mpl chimera”, Cytokine 55(3):402-408 Sep. 2011.
[cited by applicant]
Kim D-S et al: “An artificial riboswitch for controlling pre-mRNA splicing”, RNA, 11(11):1667-1677, Nov. 1, 2005.
[cited by applicant]
Kim DS et al: “Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing”, BMC molecular biology, 9(1):23, Feb. 12, 2008.
[cited by applicant]
Kim JN et al: “Design and Antimicrobial Action of Purine Analogues That Bind Guanine Riboswitches”, ACS Chemical Biology, 4(11):915-927, Nov. 20, 2009.
[cited by applicant]
Kim JN et al: “Guanine riboswitch variants from Mesoplasma florum selectively recognize 2′-deoxyguanosine”, Proceedings of the National Academy of Sciences, 104(41):16092-16097, Oct. 2, 2007.
[cited by applicant]
Kim JN et al: “Purine sensing by riboswitches”, Biology of the Cell, 100(1):1-11, Jan. 1, 2008.
[cited by applicant]
Kimura et al., “IL-7 signaling must be intermittent, not continuous, during CD8+ T cell homeostasis to promote cell survival instead of cell death”, Nature Immunology, 14(2):143-151, Dec. 16, 2012.
[cited by applicant]
Klingemann H: “Are natural killer cells superior CAR drivers?”, Oncoimmunology, 3:e28147, Apr. 15, 2014.
[cited by applicant]
Kloss et al., “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells”, Nature Biotechnology, 31(1): Dec. 16, 2012. pp. 71-75, doi:10.1038/nbt.2459.
[cited by applicant]
Kong S et al: “Suppression of human glioma xenografts with second-generation IL 13R-specific chimeric antigen receptor-modified T cells”, Clinical Cancer Research, vol. 18, No. 21, Nov. 1, 2012, pp. 5949-5960.
[cited by applicant]
Koppikar et al., “Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy”, Nature 489(7414):155-159, Sep. 2012.
[cited by applicant]
Korin YD et al: “Progression to the G1b Phase of the Cell Cycle Is Required for Completion of Human Immunodeficiency Virus Type 1 Reverse Transcription in T Cells”, Journal of Virology, 72(4):3161-3168, Apr. 1, 1998.
[cited by applicant]
Krishnamurthy J et al: “Targeting an ancient retrovirus expressed in melanoma using adoptive T-cell therapy”, Dissertation, Feb. 24, 2012, pp. 1-107.
[cited by applicant]
Kucka, Kirstin, and Harald Wajant. “Receptor Oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily.” Frontiers in Cell and Developmental Biology 8 (2021): 1890.
[cited by applicant]
Kueng et al., “General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines”, Journal of Virology, vol. 81, Issue16, May 30, 2007, pp. 8666-8676, doi: 10.1128/JVI.00682-07.
[cited by applicant]
Lamers CHJ et al: “Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity”, Molecular Therapy, 21(4):904-912, Feb. 19, 2013.
[cited by applicant]
Laminet et al: “Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagine-X-X-phosphotyrosine motifs of growth factor receptors”, J Biol Chem. 271(1):264-9, Jan. 5,…
[cited by applicant]
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities”, Molecular And Cellular Biology, vol. 8, Issue 3, Mar. 1988, pp. 1247-1252, doi: 1…
[cited by applicant]
Lee, Daniel W., et al. “ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.” Biology of Blood and Marrow Transplantation 25.4 (2019): 625-638.
[cited by applicant]
Lee, TaiSung et al: “Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling”, PLoS One. 6(8): e23396, Aug. 2017.
[cited by applicant]
Leen AM et al: “Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor”, Molecular Therapy: The Journal Of The American Society Of Gene Therapy, vol. 22, No. 6, Jun. 1, 2014, pp. 1211-1220.
[cited by applicant]
Levay A et al: “Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment”, Nucleic Acids Research, 43(12):e82, May 24…
[cited by applicant]
Li et al., “In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector”, Investigative Ophthalmology & Visual Science, vol. 35, No. 5, Apr. 1994, pp. 2543-2549, ISSN 0146-0404.
[cited by applicant]
Li et al., “Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer”, Proceedings of the National Academy of Sciences, vol. 92, No. 17, Aug. 1995, pp. …
[cited by applicant]
Lienert F et al: “Synthetic biology in mammalian cells: next generation research tools and therapeutics”, Nature reviews Molecular cell biology, 15(2):95, Jan. 17, 2014.
[cited by applicant]
Lin et al: “Allogene—Car T with Temporally-Controlled, Programmable Cytokine Signaling Outputs”, Poster Presentation 2020.
[cited by applicant]
Liu et al., “Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds”, Frontiers in Immunology, 8:38, Jan. 26, 2017.
[cited by applicant]
Lotze, Jonathan, et al. “Peptide-tags for site-specific protein labelling in vitro and in vivo.” Molecular BioSystems 12.6 (2016): 1731-1745.
[cited by applicant]
Lu X et al: “Active Conformation of the Erythropoietin Receptor: Random and Cysteine-Scanning Mutagenesis of the Extracellular Juxtamembrane and Transmembrane Domains”, Journal of Biological Chemistry, 281(11):7002-7011…
[cited by applicant]
Mandal M et al: “Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria”, Cell, 113(5):577-586, May 29, 2003.
[cited by applicant]
Mao et al., “A Graphene-Based Biosensing Platform Based on Regulated Release of an Aptameric DNA Biosensor”, Sensors (Basel), 15(11):28244-28256, Nov. 9, 2015.
[cited by applicant]
Marin V et al: “Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells”, Human Gene Therapy Methods, 23(6):376-386, Nov. 27, 2012.
[cited by applicant]
Marodon et al., “Specific transgene expression in human and mouse CD4+cells using lentiviral vectors with regulatory sequences from theCD4 gene”, Blood, May 1, 2003, vol. 101, Issue 9, pp. 3416-3423, doi: 10.1182/blood-…
[cited by applicant]
Marrack P et al: “Homeostasis of ?? TCR+ T cells”, Nature Immunology, 1(2):107-111, Aug. 2000.
[cited by applicant]
Matyjasik MM et al: “Structural basis for 2′-deoxyguanosine recognition by the 2′-dG-11 class of riboswitches”, Nucleic Acids Research, 47(20):10931-10941, Oct. 10, 2019.
[cited by applicant]
Matz MV et al: “Fluorescent proteins from nonbioluminescent
[cited by applicant]
Maurice M et al: “Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide”, Blood, vol. 99, No. 7, Apr. 1, 2002, pp. 2342-2350.
[cited by applicant]
Drachman et al: “Thrombopoietin Signal Transduction Requires Functional JAK2, Not TYK2”, Journal of Biological Chemistry 274(19): 13480-13484, May 1999.
[cited by applicant]
Drachman JG et al: “Dissecting the thrombopoietin receptor: Functional elements of the Mpl cytoplasmic domain”, Proceedings of the National Academy of Sciences 94(6):2350-2355 Mar. 18, 1997.
[cited by applicant]
Dunstan SJ et al: “Use of In Vivo-Regulated Promoters To Deliver Antigens from Attenuated
[cited by applicant]
Durand S et al: “Tailored HIV-1 Vectors for Genetic Modification of Primary Human Dendritic Cells and Monocytes”, Journal of Virology, 87(1):234-242, Oct. 17, 2012.
[cited by applicant]
Durum SK: “IL-7 and TSLP receptors: twisted sisters”, Blood, 124(1):4-5, Jul. 3, 2014.
[cited by applicant]
Eckelhart et al., “A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development”, Blood, vol. 117, No. 5, Feb. 2011, pp. 1565-1573, doi: 10.1182/blood-2010-06-291633.
[cited by applicant]
Edwards A et al: “A structural basis for the recognition of 2′-deoxyguanosine by the purine riboswitch”, Journal of molecular biology, 385(3):938-948, Nov. 5, 2008.
[cited by applicant]
Fischer UM et al: “Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect”, Stem Cells and Development, 18(5):683-692, Jun. 2009.
[cited by applicant]
Flannery et al., “Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus”, Proceedings of the National Academy of Sciences, vol. 94, No. 13, Jun. 1997, pp. 6916-6921, doi: 10.1073…
[cited by applicant]
Floss DM et al: “Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy”, Cytokine & Growth Factor Reviews, 47:1-20, Jun. 2019.
[cited by applicant]
Flotte et al., “Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vecto”, Proceedings of the National Academy of Sciences, vol. 90, No. 22, Nov. 1993, pp…
[cited by applicant]
Frecha C et al., “Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins”, Blood, vol. 112, Issue 13, Dec. 15, 2008, pp.…
[cited by applicant]
Freitas AA et al: “Population Biology of Lymphocytes: The Flight for Survival”, Annual Review of Immunology, 18 (1):83-111, Apr. 2000.
[cited by applicant]
Fuhrmann-Benzakein et al., “Inducible and irreversible control of gene expression using a single transgene”, Nucleic Acids Research, vol. 28, No. 23, 2000, e99, 5 pages, doi: 10.1093/nar/28.23.e99.
[cited by applicant]
Fukunaga et al: “Functional domains of the granulocyte colony-stimulating factor receptor”, EMBO J. 10 (10):2855-65, Oct. 1991.
[cited by applicant]
Gaffen, “Signaling Domains Of The Interleukin 2 Receptor,” Cytokine, vol. 14, No. 2, Apr. 2001, pp. 63-77.
[cited by applicant]
Gagliardi et. al., “Streamlined production of genetically modified T cells with activation, transduction and expansion in closed-system G-Rex bioreactors”, Cytotherapy, vol. 21, No. 12, Dec. 2019, pp. 1246-1257, doi: 10…
[cited by applicant]
Garst AD et al: “Riboswitches: structures and mechanisms”, Cold Spring Harbor perspectives in biology, 3(6): a003533, Oct. 18, 2010.
[cited by applicant]
Geron, “The role of TSLP pathway in the development of B-cell Acute Lymphoblastic Leukemia”, Thesis, Dec. 31, 2018, 144 pages.
[cited by applicant]
Ghassemi et. al., “Rapid manufacturing of non-activated potent CAR T cells”, Nature Biomedical Engineering, vol. 6, Feb. 21, 2022, pp. 118-128, doi: 10.1038/s41551-021-00842-6, ISSN 2157-846X.
[cited by applicant]
Ghosh A et al: “CAR T-Cell Therapies: Current Limitations & Future Opportunities”, Cell & Gene, Sep. 26, 2010.
[cited by applicant]
Gotthardt et al: “JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation”, Frontiers in Immunology 10:2590, Nov. 12, 2019 pp. 1-16.
[cited by applicant]
Goyvaerts et al. “Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells”, Gene Therapy (12) 1133-1140, 2012.
[cited by applicant]
Grindley et al., “Mechanisms of Site-Specific Recombination”, Annual Review of Biochemistry, vol. 75, Issue 1, Mar. 16, 2006, pp. 567-605, doi: 10.1146/annurev.biochem.73.011303.073908.
[cited by applicant]
Groher F et al: “Synthetic riboswitches—A tool comes of age”, Biochimica et Biophysica Acta, 1839(10):964-973, May 17, 2014.
[cited by applicant]
Guerrero-Esteo, Mercedes et al. “Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II.” The Journal of biological chemistry vol. 277,32 (2002): 29197-209…
[cited by applicant]
Gurney ei al: “Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation”, Proceedings of the National Academy of Sciences 92(12):5292-5296, Jun. 6, 199…
[cited by applicant]
Harborne NR et al: “Transcriptional control, translation and function of the products of the five open reading frames of the
[cited by applicant]
Harris KA et al: “Biochemical analysis of pistol self-cleaving ribozymes”, RNA, 21(11):1852-1858, Sep. 18, 2015.
[cited by applicant]
Hatakeyama et al., “A Restricted Cytoplasmic Region Of IL-2 Receptor β Chain Is Essential for Growth Signal Transduction but Not for Ligand Binding And Internalization,” Cell, vol. 59, Issue 5, Dec. 1, 1989, pp. 837-845.
[cited by applicant]
He X et al: “Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases”, Journal of Hematology & Oncology 6(1):11 2013, pp. 1-8.
[cited by applicant]
Hinrichs CS and Rosenberg SA: “Exploiting the curative potential of adoptive T-cell therapy for cancer”, Immunological Reviews, vol. 257, No. 1, Jan. 13, 2014, pp. 56-71.
[cited by applicant]
Hitchcock et al., “YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation”, Blood 112(6):2222-31, Sep. 15, 2008.
[cited by applicant]
Hoyos V et al: “Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety”, Leukemia, 24(6):1160-1170, Apr. 29, 2010.
[cited by applicant]
Hsieh C et al: “Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages”, Science, 260(5107):547-549, Apr. 23, 1993.
[cited by applicant]
Huang et al., “The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor”, Molecular Cell, vol. 8, Issue 6, Dec. 2001, pp. 1327-1338, doi: 10.1016/s1…
[cited by applicant]
Huck et al., “Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C gamma genes”, Nucleic Acids Research, vol. 14, No. 4, Feb. 4, 1986, pp. 1779-1789, doi: 10.109…
[cited by applicant]
Hunter MR et al: “Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes”, Molecular Immunology, 56(1-2):1-11, Nov. 2013.
[cited by applicant]
Hurton LV et al: “Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor- specific T cells”, Proceedings of the National Academy of Sciences, 113(48):E7788-E7797, Nov. 14, 2016.
[cited by applicant]
Abe et al: “A novel MPL point mutation resulting in thrombopoietin-independent activation”, Leukemia 16 (8):1500-1506, Aug. 2002.
[cited by applicant]
Adachi K et al: “IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor”, Nature Biotechnology, 36(4):346-351, Mar. 5, 2018.
[cited by applicant]
Ahn H-J et al: “Requirement for Distinct Janus Kinases and STAT Proteins in T Cell Proliferation Versus IFN-gamma Production Following IL-12 Stimulation”, Journal of Immunology, 161(11):5893-5900, Dec. 1, 1998.
[cited by applicant]
Alexander et al. “Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation”, EMBO J. 15(23):6531-40, Dec. 2, 1996.
[cited by applicant]
Ali et al., “Adeno-Associated Virus Gene Transfer to Mouse Retina”, Human Gene Therapy, vol. 9, Issue 1, Jan. 1, 1998, p. 81-86, doi: 10.1089/hum.1998.9.1-81.
[cited by applicant]
Ali et al., “Gene transfer into the mouse retina mediated by an adeno-associated viral vector”, Human Molecular Genetics, vol. 5, Issue 5, 1996, pp. 591-594, doi: 10.1093/hmg/5.5.591.
[cited by applicant]
Al-Lazikani, B., Lesk, A. M., & Chothia, C. (1997). Standard conformations for the canonical structures of immunoglobulins. Journal of molecular biology, 273(4), 927-948.
[cited by applicant]
Alpuche Aranda CM et al: “
[cited by applicant]
Anthony PC et al: “Folding energy landscape of the thiamine pyrophosphate riboswitch aptamer”, Proceedings of the National Academy of Sciences, 109(5):1485-1489, Jan. 4, 2012.
[cited by applicant]
Armstrong AJ et al: “ATP-Binding Cassette Transporter G1 Negatively Regulates Thymocyte and Peripheral Lymphocyte Proliferation”, Journal of Immunology, 184(1):173-183, Jan. 1, 2010.
[cited by applicant]
Beisel CL et al: “Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing”, Nucleic acids research, 39(7):2981-2994, Dec. 11, 2010.
[cited by applicant]
Belay E et al: “A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor”, Blood 125(6):1025-1033 Feb. 5, 2015.
[cited by applicant]
Bénit L et al: “Characterization of mpl cytoplasmic domain sequences required for myeloproliferative leukemia virus pathogenicity.”, Journal of Virology 68(8):5270-5274 1994.
[cited by applicant]
Bennett et al., “Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction”, Investigative Ophthalmology & Visual Science, vol. 38, No. 13, Jul. 30, 1997, pp. 2857-2863, ISSN 0146…
[cited by applicant]
Berens C et al: “RNA aptamers as genetic control devices: The potential of riboswitches as synthetic elements for regulating gene expression”, Biotechnology Journal, 10(2):246-257, Feb. 10, 2015.
[cited by applicant]
Biosettia et al., “pLV-miRNA Expression Vector System”, Manual, May 2005, pp. 1-14.
[cited by applicant]
Blau C A et al: “A proliferation switch for genetically modified cells”, Proceedings of the National Academy of Sciences 94(7):3076-3081, Apr. 1997.
[cited by applicant]
Blø M et al., “Enhanced gene expression from retroviral vectors”, BMC Biotechnology, 8:19, Feb. 25, 2008, pp. 1-6.
[cited by applicant]
Bork, “Powers and pitfalls in sequence analysis: the 70% hurdle”, Genome Research, vol. 10, Issue 4, Apr. 2000, pp. 398-400, doi: 10.1101/gr.10.4.398.
[cited by applicant]
Borrás et al., “Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow. Relevance for potential gene therapy of glaucoma”, Gene Therapy, vol. 6, No. 4, Oct. 28, 1998, pp.…
[cited by applicant]
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”, Science, New York, N.Y., vol. 247, Issue 4948, Mar. 16, 1990, pp. 1306-1310, doi: 10.1126/science.2315699.
[cited by applicant]
Brown RJ et al: “Model for growth hormone receptor activation based on subunit rotation within a receptor dimer”, Nature Structural & Molecular Biology, 12(9):814-821, Aug. 21, 2005.
[cited by applicant]
Budde LE et al: “Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma”, PLOS One, vol. 8, No. 12, Dec. 17,…
[cited by applicant]
Burchill, et.al., “Interleukin-w Receptor Signaling in Regulatory T Cell Development and Homeostasis,” Immunology Letters, vol. 114, Issue 1, Nov. 30, 2007, pp. 1-8.
[cited by applicant]
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single…
[cited by applicant]
Burns JC et al: “Vesicular Stomatitis Virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells”, Proceedings National Academ…
[cited by applicant]
Burton, “Immunoglobulin G: Functional sites”, Molecular Immunology, vol. 22, Issue 3, 1985, pp. 161-206, doi: 10.1016/0161-5890(85)90151-8.
[cited by applicant]
Busch, S J, and P Sassone-Corsi. “Dimers, leucine zippers and DNA-binding domains.” Trends in genetics : TIG vol. 6,2 (1990): 36-40. doi:10.1016/0168-9525(90)90071-d.
[cited by applicant]
Carneiro et al: “Co-expression of chimeric antigen receptor (CAR) and miRNAs to T cell therapy”, European Journal of Cancer, 50(5):S219, 2014.
[cited by applicant]
Cavalieri et al., “Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence”, Blood, vol. 102, No. 2, Jul. 15, 2003, pp. 497-505, doi: 10.1182/blood-2003…
[cited by applicant]
Chatfield SN et al: “Use of the nirB promoter to direct the stable expression of heterologous antigens in
[cited by applicant]
Chen YY et al: “Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems”, Proceedings of the National Academy of Sciences, 107(19):8531-8536, Apr. 26, 2010.
[cited by applicant]
Chinnasamy D et al: “Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins”, Blood, 96(4):1309-1316, Aug. 15, 2000.
[cited by applicant]
Chmielewski M et al: “Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma”, Immunological Reviews, 257(1):83-90, Jan. 2014.
[cited by applicant]
Chothia, Cyrus, and Arthur M. Lesk. “Canonical structures for the hypervariable regions of immunoglobulins.” Journal of molecular biology 196.4 (1987): 901-917.
[cited by applicant]
Chothia, Cyrus, et al. “Conformations of immunoglobulin hypervariable regions.” Nature 342.6252 (1989): 877-883.
[cited by applicant]
Chothia, Cyrus, et al. “Structural repertoire of the human VH segments.” Journal of molecular biology 227.3 (1992): 799-817.
[cited by applicant]
Coffin et al., Retroviruses, Cold Spring Harbor Laboratory Press, 1997, pp. 758-763, ISBN-10: 0-87969-571-4.
[cited by applicant]
Colby DW et al: “Engineering Antibody Affinity by Yeast Surface Display”, Methods in Enzymology, 388:348-358, 2004.
[cited by applicant]
Constantinescu et al: “The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif”, Mol Cell. 7(2):377-85, Feb. 2001.
[cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect”, Blood, vol. 101, Issue 4, Feb. 15, 2003, pp. 1637-1644, doi: 10.1182/blo…
[cited by applicant]
Costello et al., “Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors”, Gene Therapy, vol. 7, Issue 7, Apr. 2000, pp. 596-604, doi: 10.1038/sj.gt.3301135.
[cited by applicant]
Cruz CR et al: “Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience”, Cytotherapy, 12(6):743-749, Oct. 2010.
[cited by applicant]
Cui et al: “Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors”, Proceedings of the National Academy of Sciences 118(2), Jan. 12, 2021.
[cited by applicant]
Dahlen DD et al: “Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs”, Blood 102 (1):102-108 Jul. 1, 2003.
[cited by applicant]
Dambach MD et al: “Expanding roles for metabolite-sensing regulatory RNAs”, Current opinion in microbiology, 12 (2):161-169, Feb. 26, 2009.
[cited by applicant]
Dardalhon et al: “Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector”, Blood. Aug. 1, 2000;96(3):885-93.
[cited by applicant]
Desai SK et al: “Genetic Screens and Selections for Small Molecules Based on a Synthetic Riboswitch That Activates Protein Translation”, Journal of the American Chemical Society, 126(41):13247-13254, Oct. 20, 2004.
[cited by applicant]
Dostert, Catherine, et al. “The TNF family of ligands and receptors: communication modules in the immune system and beyond.” Physiological reviews 99.1 (2019): 115-160.
[cited by applicant]
Brockstedt et al., “Induction of Immunity to Antigens Expressed by Recombinant Adeno-Associated Virus Depends on the Route of Administration”, Clinical Immunology, vol. 92, Issue 1, Jul. 1999, pp. 67-75, doi.org/10.1006…
[cited by applicant]
Dotti et al., “Design and development of therapies using chimeric antigen receptor-expressing T cells”, Immunological Reviews, vol. 257, Issue 1, Jan. 2014, pp. 107-126, doi: 10.1111/imr. 12131.
[cited by applicant]
Ehsanipour et al., “Injectable, Hyaluronic Acid-Based Scaffolds with Macroporous Architecture for Gene Delivery”, Cellular and Molecular Bioengineering, vol. 12, Sep. 4, 2019, pp. 399-413.
[cited by applicant]
Henry et al., “Hydroxyethyl starch-based preservation solutions enhance gene therapy vector delivery under hypothermic conditions”, Liver Transplantation, vol. 14, Issue 12, Dec. 24, 2008, pp. 1708-1717, doi.org/10.1002…
[cited by applicant]
Kochenderfer et at., “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor”, Journal of Immunotherapy, vol. 32, Issue 7, Sep. 2009, pp. 689-702, doi: 10.1097/CJI.0b013e3181ac6138.
[cited by applicant]
Lamer et al, “Retroviral vectors for clinical immunogene therapy are stable for up to 9 years”, Cancer Gene Therapy, vol. 15, Jan. 18, 2008, pp. 268-274, doi:10.1038/sj.cgt.7701114.
[cited by applicant]
Lu et. al., “A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies”, Human Gene Therapy Methods, vol. 27, No. 6, Dec. 2016, pp. 209-218, doi:10.1089/hgtb.2016.120.
[cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor design”, Cancer Discovery, vol. 3, Issue 4, Apr. 2013, pp. 388-398, doi: 10.1158/2159-8290.CD-12-0548.
[cited by applicant]
Stoner et al., “Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systemic Review”, The Patient—Patient-Centered Outcomes Research, vol. 8, 2015, pp. 145-153, doi:10.1007/s40271-014-0075-y.
[cited by applicant]
Cited By (1)